<DOC>
	<DOCNO>NCT00492466</DOCNO>
	<brief_summary>This study find Interferon-beta recover effectiveness patient Multiple Sclerosis previously develop neutralize antibody Interferon-Beta .</brief_summary>
	<brief_title>Investigating Interferon-Beta Can Used Patients With MS After They Have Developed Neutralizing Antibodies</brief_title>
	<detailed_description>This multi-center , open Label , non-comparative Phase IV trial . Eligible Patients receive treatment Interferon-beta-1a ( AVONEX ) 30mcg I.M . weekly 12 month . In wash-out period prior commence treatment AVONEX , patient receive treatment intermittent Methylprednisolone 500 mg PO Daily three consecutive day monthly interval . The patient examine clinically laboratory test perform screen ( month -1 ) 3 , 9 , 15 month . Neutralizing antibody ( NAb ) titres Binding antibody ( BAb ) titres well MxA protein level evaluate screening/baseline ( month -1/0 ) 3 , 6 , 9 , 12 , 15 month .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Interferon-beta</mesh_term>
	<mesh_term>Interferon beta-1a</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>Relapsing remit Multiple Sclerosis accord Poser criterion ( CDMS LDMS ) Multiple Sclerosis accord McDonald criterion Disability equivalent EDSS 6.0 less Clinical activity define least one relapse rate within last 12 month NAb titre &gt; 20 ( measure least 48 hour last interferonbeta injection treat subcutaneously administer interferonbeta1b interferonbeta1a ( Rebif ) least 24 hour enrollment Any condition might give rise similar symptom MS Immunomodulatory therapy interferonbeta1a interferonbeta1b immunosuppressive treatment six month prior inclusion trial Treatment glucocorticoid ACTH le one month prior inclusion trial History major depression Alcohol drug dependency Cardiac insufficiency , cardiomyopathy , significant cardiac dysrhythmia , unstable advanced ischemic heart disease ( NYHA III IV ) hypertension ( BP &gt; 180/110 mmHg ) Renal insufficiency define serum creatinine &gt; 1.5 time upper normal reference limit Any systemic disease influence patient 's safety compliance , evaluation disability Gastrointestinal ulcer , gastritis , dyspepsia Women pregnant , breastfeed possibility pregnancy trial . To avoid pregnancy , woman postmenopausal , surgical sterile , sexually inactive practice reliable contraceptive</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2008</verification_date>
	<keyword>Multiple Sclerosis</keyword>
	<keyword>antibody</keyword>
	<keyword>Neutralizing antibody</keyword>
	<keyword>Binding antibody</keyword>
	<keyword>MxA protein</keyword>
</DOC>